Language: English
References: 0
Page: 3
PDF size: 139.25 Kb.

Text Extraction

Whether or not the so-called curse, “May you live in interesting times” is apocryphal, we have to acknowledge that we do indeed live in interesting times. It has been only three months since the October 2016 issue of MEDICC Review, but the changes since—in many directions—have been head-spinning.
For starters, scientists at Roswell Park Cancer Institute have launched a clinical trial of CIMAvax, the therapeutic lung cancer vaccine developed at Cuba’s Molecular Immunology Center, surely a win–win for the citizens of both countries. The vaccine, intended to lengthen life and restore quality of life to people suffering from non-small cell lung cancer, has already been used for thousands of patients in Cuba and abroad. Cuban researchers say that the aim of such cancer immunotherapies is to use them in combination with others to convert cancer from a life-threatening condition to a chronic disease.